Susan Abu-Absi
Chief Operating OfficerDr. Susan Abu-Absi, Ph.D., is Chief Operating Officer of Aura Biosciences, Inc. from August 2026. She was Chief Operating Officer of Be Biopharma, Inc. from March 2025. She served as Chief Technology Officer at 2seventy bio, Inc. since February 2022 until 2024. She also served as Chief Manufacturing Officer at 2seventy bio, Inc. from February 2022 until 2023. Prior to these roles, she was the Senior Vice President, Head of Manufacturing & Head of Technical Development & Operations at 2seventy bio, Inc. until February 2022. Dr. Abu-Absi has extensive experience in biologics and cell & gene therapy process development and manufacturing. Previously, she led the oncology manufacturing organization at bluebird bio, having joined in 2017 as Head of Process and Analytical Development and advancing through roles of increasing responsibility during her tenure. Before joining bluebird, she spent years in the Global Product Development & Supply organization at Bristol Myers Squibb, supporting clinical and commercial biologics drug substance manufacturing at internal sites and at contract manufacturers. Prior to BMS, she was a member of the Process Sciences organization at Bayer Healthcare in Berkeley, California. Dr. Abu-Absi has led several teams developing manufacturing processes, analytical methods and CMC packages for license applications, directly contributing to the approval of seven products, including Abecma, Zynteglo and Skysona. With over 20 years of experience in strategic operations, product development and manufacturing in the biotechnology industry, Dr. Abu-Absi brings a wealth of knowledge and expertise to her role, positioning Be Bio for continued growth and operational excellence. Her career has been marked by leadership in the development and manufacturing of biologics and cell and gene therapies, contributing to the approval of several key products, including Abecma, Zynteglo, Skysona, Yervoy and Opdivo. Most recently, Dr. Abu-Absi built the global manufacturing and supply infrastructure at 2seventy bio and managed strategic partnerships with academics, partner innovator companies and suppliers to enable the translation of four novel cell therapies into the clinic. She earned a Ph.D. in Chemical Engineering from the University of Minnesota, where she was a National Science Foundation Fellow and a B.S. in Chemical Engineering, summa cum laude with honors, from the University of Toledo (Toledo, Ohio).
Positions
- Company NameAura Biosciences, Inc.Stock CodeAURAPositionChief Operating OfficerColleagues
- JJJ. Jill HopkinsChief Medical Officer & President of Research and Development
- DMDavid Michael JohnsonIndependent Chairman of the Board
- NCNatalie C. HollesPresident, CEO & Director
- AEAmy ElazzouziSenior Vice President of Finance, Treasurer and Secretary
- ADAlex DasallaHead of Investor Relations & Corporate Communications
- GMGiovanni MariggiIndependent Director
- SSSapna SrivastavaIndependent Director
- AMAntony MattessichIndependent Director
